Featured News

DDW is hosting its first hybrid event. This year, you have the choice to attend in person in San Diego or virtually through their cutting-edge platform.

Anokion SA announced successful completion of its Phase 1 clinical trial evaluating KAN-101 for the treatment of celiac disease, with promising results.

A study from the University of Chicago has demonstrated that B-cells are required for the development of villous atrophy (intestinal damage) in celiac disease. This finding provides support for the exploration of B-cell–directed therapies for the treatment of celiac disease.

Celiac disease patients are at an increased risk, albeit small, of cancer, and the findings from these studies confirm the importance of a healthy immune system in cancer prevention. For patients with celiac disease, adhering to a strict, gluten-free diet is critical to maintaining a healthy immune system.

Researchers found higher rates of skin disease in patients with celiac disease compared to controls, including increased risks for eczema, psoriasis, urticaria, vitiligo, acne, and alopecia areata.

researchers concluded that patients with celiac disease who are infected with COVID-19 are not at higher risk of hospitalization.

I am pleased to share a research grant awarded to the Dubcovsky Lab at UC Davis for Development of a Novel Dietary Treatment for Celiac Disease that may significantly reduce the suffering experienced by our patient community.

Thanks to your support, we have been remarkably successful in advancing our shared mission over the past year. What follows are some highlights of some of our most important accomplishments.

My appointment to PCORI’s Advisory Panel on Patient Engagement has just ended. It was a productive and enlightening three-year engagement that has helped inform my ongoing service to the celiac…

We are proud to announce that the Celiac Disease Foundation has received a 100 Overall Score from Charity Navigator.